Compare Moderna, Inc. (MRNA) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Wipro Limited — how do they compare? Moderna, Inc. trades at $206.52 (market cap $78.65B), while Wipro Limited trades at $1.71 (market cap $16.22B). The key difference: Moderna, Inc. is far larger — about 4.8× Wipro Limited's market cap, and Wipro Limited pays a 5.19% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Wipro Limited for 41 Days on average.
| MRNA | WIT | |
|---|---|---|
Market Cap | $78.65B | $16.22B |
Volume | 37,373,437 | 9,028,667 |
Sector | Health | Technology |
52-Week High | $203.46 | $3.06 |
52-Week Low | $22.36 | $1.61 |
Typical Hold Time | 59 Days | 41 Days |
Enterprise Value | $74.80B | $14.33B |
Dividend Yield | — | 5.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
WIT trades at $1.67, down 0.6% on the day, with a bearish technical signal from moving averages and a neutral stance from oscillators. The company reported revenue of $890.88 billion in 2025 with a net income margin of 13.92%, though recent quarters have seen earnings misses against expectations. Recent news highlights Wipro's AI initiatives boosting productivity and new cybersecurity partnerships.
The outlook is mixed; valuation ratios like a P/E of 12.78 appear reasonable, but analyst consensus is cautious with only 19% buy ratings. Key risks include competitive pressures and macroeconomic uncertainty affecting tech spending. Upside hinges on execution of AI strategies and reversing earnings misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
